Abstracts tagged "Systemic sclerosis"

Abstract Number: 1072 • 2019 ACR/ARP Annual Meeting
CCR2+ Circulating Monocytes Contribute to the Survival of ADSC in Bleomycin-Induced Skin Fibrosis
Madhavi Latha Chalasani¹, Liyoung Kim ¹ and Theresa Lu ², ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, Weill Cornell Medicine (Microbiology and Immunology), New York
Background/Purpose: Monocytes and monocyte-derived cells play a crucial role during homeostasis and also during the development of various inflammatory diseases including skin fibrosis. Ly6Chi inflammatory…
Abstract Number: 1655 • 2019 ACR/ARP Annual Meeting
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
Kimberly Showalter¹, Cynthia Magro ², Dana Orange ³, Yaxia Zhang ⁴, Phaedra Agius ⁵, Jackie Finik ⁶, Robert Spiera ¹ and Jessica Gordon ¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, ³Rockefeller University, New York, ⁴Hospital for Special Surgery, New York, ⁵New York Genome Center, New York City, ⁶Hospital for Special Surgery, New York, NY, New York, NY
Background/Purpose: The association between systemic sclerosis (SSc) skin histology and clinical findings is not fully characterized. In two SSc trials, we developed a scoring system…
Abstract Number: 2597 • 2019 ACR/ARP Annual Meeting
Prevalence and Clinical Associations of Degos Lesions in Systemic Sclerosis
Paula Song¹, Melody Chung ², Shufeng Li ³, David Fiorentino ⁴ and Lorinda Chung ², ¹Department of Medicine, Santa Clara Valley Medical Center, Palo Alto, CA, ²Stanford University, Palo Alto, CA, ³Division of Immunology and Rheumatology, Department of Medicine, Stanford, Palo Alto, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Redwood City, CA
Background/Purpose: Degos disease, also known as malignant atrophic papulosis (MAP), is a rare small-vessel vasculopathy that has characteristic cutaneous manifestations consisting of erythematous telangiectatic rims…
Abstract Number: 2744 • 2019 ACR/ARP Annual Meeting
Altered Expression of CD52 Facilitates Adhesion of Circulating CD14+ Monocytes in Systemic Sclerosis
Michal Rudnik¹, Mara Stellato ¹, Filip Rolski ², Przemyslaw Blyszczuk ³, Karin Klingel ⁴, Joerg Henes ⁵, Carol Feghali-Bostwick ⁶, Oliver Distler ⁷ and Gabriela Kania ³, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²Department of Clinical Immunology, Jagiellonian University Medical College, Krakow, Poland, ³Centre of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁴Institute for Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany, ⁵University Hospital Tuebingen, Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Tuebingen, Germany, ⁶Division of Rheumatology & Immunology, Medical University of South Carolina, Charlston, SC, ⁷Dept. of Rheumatology, University Hospital Zürich, Zürich, Switzerland, Zürich, Switzerland
Background/Purpose: Infiltration of inflammatory cells, including monocytes, into the organs is a major process leading to fibrosis, remodelling and organ dysfunction in systemic sclerosis (SSc).…
Abstract Number: 262 • 2019 ACR/ARP Annual Meeting
Outpatient Healthcare Utilization Among Incident Cases of Systemic Sclerosis: Results from a Population-based Cohort (1988-2016)
Caitrin Coffey¹, Avneek Singh Sandhu ², Cynthia Crowson ³, Dennis Asante ¹, Eric Matteson ⁴, Thomas Osborn ⁵, Kenneth Warrington ⁶ and Ashima Makol ⁵, ¹Mayo Clinic, Rochester, MN, ²kettering health, dayton, OH, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA, Rochester, ⁵Mayo Clinic Minnesota, rochester, MN, ⁶Mayo Clinic Rochester, Rochester, MN
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disorder which results in multi-organ dysfunction and high morbidity and mortality. There is limited data on healthcare…
Abstract Number: 727 • 2019 ACR/ARP Annual Meeting
Mortality and Morbidity in Scleroderma Renal Crisis: A Systematic Literature Review
Hyein Kim¹, Frédéric Lefebvre ², Sabrina Hoa ³ and Marie Hudson ⁴, ¹The University of British Columbia, Vancouver, Canada, ²University of Montreal, Montreal, Canada, ³University of Montreal, Montreal, QC, Canada, ⁴Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: The introduction of angiotensin converting enzyme (ACE) inhibitors in the early 1970s resulted in marked improvement in clinical outcomes of scleroderma renal crisis (SRC).Despite…
Abstract Number: 1044 • 2019 ACR/ARP Annual Meeting
TGF-β Isoforms Modulate the RNA Cargo of Extracellular Vesicles (Exosomes) Isolated from Cultured Normal Human Lung Microvascular Endothelial Cells: A Mechanistic Link Between Endothelial Cell Dysfunction and the Establishment of a Profibrotic Phenotype in SSc?
Peter Wermuth¹ and Sergio Jimenez ¹, ¹Jefferson Institute of Molecular Medicine and Division of Connective Tissue Diseases, Thomas Jefferson University, Philadelphia, PA, Philadelphia, PA
Background/Purpose: Extracellular vesicles (EV) are a diverse assortment of lipid bilayer-bound vesicles of various sizes and origin. Exosomes are a subset of EV arising from…
Abstract Number: 1629 • 2019 ACR/ARP Annual Meeting
Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
Yasser Radwan¹, Tina Gunderson ², Cynthia Crowson ³, Alicia Hinze ¹, Kevin Moder ⁴, Floranne Ernste ⁴, Shreyasee Amin ⁴, Uma Thanarajasingam ², Thomas Osborn ¹, Kenneth Warrington ⁴, Paul Wennberg ⁴ and Ashima Makol ¹, ¹Mayo Clinic Minnesota, rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic Rochester, Rochester, ⁴Mayo Clinic Rochester, rochester, MN
Background/Purpose: Nailfold videocapillaroscopy (NVC) is a simple, non-invasive & highly sensitive tool to evaluate structural abnormalities of the microcirculation in vivo and considered a key…
Abstract Number: 1656 • 2019 ACR/ARP Annual Meeting
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
Michael Kreuter ¹, Anna Maria Hoffmann-Vold ², Marco Matucci-Cerinic ³, Lesley Saketkoo ⁴, Kristin Highland⁵, Hilary Wilson ⁶, Margarida Alves ⁷, Nils Schoof ⁶ and Toby Maher ⁸, ¹Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Member of the German Center for Lung Research, Germany, Germany, Germany, ²Department of Rheumatology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, ³University of Florence, Department of Medicine, Florence, Italy, Florence, Italy, ⁴New Orleans Scleroderma and Sarcoidosis Patient Care and Research Center, New Orleans; Tulane University School of Medicine, University Medical Center – Comprehensive Pulmonary Hypertension Center, USA, New Orleans, ⁵Cleveland Clinic, Cleveland, Ohio, USA, Cleveland, OH, ⁶Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, ⁷Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁸National Heart and Lung Institute, Imperial College London, UK and National Institute for Health Research Clinical Research Facility, Royal Brompton Hospital, London, UK, London, United Kingdom
Background/Purpose: SSc-ILD is a major cause of morbidity and mortality in patients with systemic sclerosis. A subset of patients with SSc-ILD show a decline in…
Abstract Number: 2598 • 2019 ACR/ARP Annual Meeting
Different Treatment Backgrounds Do Not Influence Aminaphtone Efficacy in Primary and Secondary Raynaud’s Phenomenon
Alberto Sulli¹, Federica Goegan ², Emanuele Gotelli ², Massimo Patane' ³, Carmen Pizzorni ³, Sabrina Paolino ³, Elisa Alessandri ⁴ and Barbara Ruaro ⁵, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genova, Italy., Genoa, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS San Martino Polyclinic Hospital, Genoa, Italy, Genova, ⁵1 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, IRCCS Ospedale Policlinico San Martino, Genoa, Italy; 2 Cardinal Ferrari Centre, S. Stefano Rheabilitation, Fontanellato (Parma), Italy, Genoa, Italy
Background/Purpose: Aminaphtone treatment improves clinical symptoms of Raynaud's phenomenon (RP) and increases peripheral blood perfusion (BP) in patients with either primary or secondary RP (1-2).The…
Abstract Number: 2747 • 2019 ACR/ARP Annual Meeting
Identification of Naturally Presented Peptides of the Autoantigen Topoisomerase-I Reveals a Common Pathogenic Mechanism in Patients with Systemic Sclerosis
Eleni Tiniakou¹, Andrea Fava ², Zsuzsanna McMahan* ³, Tara Gurh ⁴, Robert O'Meally ⁴, Ami Shah ⁵, Frederick Wigley ³, Robert Cole ⁴, Francesco Boin ⁶ and Erika Darrah ¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Johns Hopkins University, Division of Rheumatology, Baltimore, ⁴Johns Hopkins University, Baltimore, ⁵Johns Hopkins Hospital, Baltimore, MD, ⁶UCSF, San Francisco, CA
Background/Purpose: Autoimmune responses to DNA topoisomerase-I (TOP1) are found in a subset of patients with scleroderma at high risk for interstitial lung disease (ILD) and…
Abstract Number: 389 • 2019 ACR/ARP Annual Meeting
ACR/EULAR Criteria for Myositis and Systemic Sclerosis Lack Sensitivity for Scleromyositis
Alain Meyer¹, Valérie Leclair ², Océane Landon-Cardinal ³, Benjamin Ellezam ⁴, Julie D'Aoust ⁵, Margherita Giannini ⁶, Bernard Geny ⁶, Laurent Arnaud ⁷, Jacques-Eric Gottenberg ⁸, Jean Sibilia ⁹, Minoru Satoh ¹⁰, Marvin Fritzler ¹¹, Yves Troyanov ¹² and Marie Hudson ¹³, ¹Centre de Reference des Maladies Autoimmunes Rares, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Division of Rheumatology, Department of Medicine, Jewish General Hospital; Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Montreal, QC, Canada, ³Centre Hospitalier de l'Université de Montréal, Montréal, Canada, ⁴Department of Pathology, Centre Hospitalier Universitaire Sainte-Justine, Montréal, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶CHU de Strasbourg, Strasbourg, France, ⁷Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹CHU Strasbourg, Strasbourg, France, ¹⁰Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹¹Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹²Division of Rheumatology, Department of Medicine, Hôpital du Sacre-Coeur de Montreal, Montreal, QC, Canada, ¹³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada
Background/Purpose: Autoimmune myositis consists of a group of diseases with heterogeneous muscular and systemic manifestations. Prognosis also varies widely across the spectrum. Thus, myositis subgroups…
Abstract Number: 729 • 2019 ACR/ARP Annual Meeting
Modelled Patient Level Skin Score Trajectory Predicts Risk of Death or Major Organ-Based Complications in Diffuse Cutaneous Systemic Sclerosis
Svetlana Nihtyanova¹, Emma Derrett-Smith ¹, Carmen Fonseca ¹, Voon Ong ² and Christopher Denton ³, ¹UCL Medical School, Royal Free Campus, London, United Kingdom, ²UCL Medical School, Royal Free Campus, London, ³University College London Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, London, UK, London, United Kingdom
Background/Purpose: For most patients with diffuse cutaneous systemic sclerosis (dcSSc), skin thickness improves over time, especially with background immunosuppressive treatment. This has reduced confidence in…
Abstract Number: 1046 • 2019 ACR/ARP Annual Meeting
The Effect of Nintedanib versus Mycopheolate Mofetil in the FRA2 Mouse Model of Systemic Sclerosis Associated Interstitial Lung Disease
Thuong Trin-Minh ¹, Yun Zhang ², Jörg Distler ³ and Lutz Wollin⁴, ¹University Erlangen-Nuremberg, Erlangen-Nuremburg, Germany, ²University Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, Erlangen, Germany, ⁴oehringer Ingelheim, Biberach, Germany
Background/Purpose: Interstitial lung disease (ILD) is a key driver of mortality in patients with systemic sclerosis (SSc). In lack of approved treatment it constitutes a…
Abstract Number: 1630 • 2019 ACR/ARP Annual Meeting
Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Takashi Nawata¹, Mikito Suzuki ², Yuichiro Shirai ³ and Masataka Kuwana ³, ¹1. Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan. 2. Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan, Tokyo, Japan, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Tokyo, Japan, ³Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, Bunkyo-ku, Tokyo, Japan
Background/Purpose: Interstitial lung disease (ILD) is the leading causes in patients with systemic sclerosis (SSc). Forced vital capacity (FVC) is routinely used for assessment of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].